Cyclin-Dependent Kinase (CDK) Inhibitors Therapeutics Pipeline Projects Vast Growth Ahead     |    CAD Software Market to Reach $11,097 Million by 2023     |    Friedreich’s Ataxia (FRDA) Therapeutics Pipeline to Receive Various Drug Designations from the USFDA and EMA in the Coming Years
P&S Market Research - A market research firm

Oral Mucositis Therapeutics Pipeline Analysis

P&S Market Research-Oral Mucositis Therapeutics Pipeline Analysis report

Oral Mucositis Therapeutics Pipeline Analysis 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: June 2017
Report Code: LS11024
Available Format: pdf
Pages: 93

Pipeline Overview

Oral mucositis is the most common complication of chemotherapy, and occurs usually in the people suffering from head and neck cancer. It causes damage to mucosal lining of the mouth which results in formation of ulcers and infections. The disease occurs usually occurs after 5 to 10 days of a chemotherapy process in cancer patients. Oral mucositis leads to different problems such as severe pain in mouth, lack of nutrition due to inability to eat, increased risk of infections due to open sores in the oral cavity. The disease usually lasts for one week to six weeks or more.

Some of the symptoms associated with oral mucositis are open sores or bleeding, pain, redness or swelling, white patches, dry mouth, diarrhea, nausea, blood in mouth, thicker saliva in the mouth and difficulty in talking or swallowing. Oral mucositis can be treated by using antiseptic mouth rinses, pain killer medicines, water-soluble lubricating agents, bland rinses and mucosal coating agents.

 

ORAL MUCOSITIS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

Oral Mucositis Therapeutics Pipeline Analysis

Drug manufacturing companies are constantly in the quest to find better and new treatment strategies with potential targets such as glucocorticoid receptor and superoxide dismutase which can also prove to be effective in oral mucositis treatment. The U.S. Food and Drug Administration (USFDA) has granted various designations including orphan drug and fast track status to many drugs which are driving the growth of the pipeline.

Pipeline Analysis

As of May 2017, the oral mucositis pipeline comprises approximately 18 active drug candidates in different stages of development.

Competitive Landscape

Some of the other key players developing drugs for the treatment of oral mucositis include Daewoong Pharmaceutical Co., Ltd., Cellceutix Corporation, Soligenix, Inc. and others.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the latest stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

1850
Group License

Group License authorizes access of the publication upto 5 users.

2500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

5000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment